Clinical Trials Sponsored by C Rheaume

Total 552 results

Bial - Portela C S.A.

Completed

Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites

Epilepsy

Germany
Bial - Portela C S.A.

Completed

Bioequivalence of Two Different Sources of Eslicarbazepine Acetate

Epilepsy
Bial - Portela C S.A.

Completed

Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" Phenomenon

Parkinson Disease
Bial - Portela C S.A.

Completed

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Effect of Food on BIA 6-512 (Trans-resveratrol)

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Tolerability and Steady-state Pharmacokinetics of BIA 6-512

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and Metabolites

Hypertension | Congestive Heart Failure

Switzerland
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

Parkinson's Disease (PD)

France
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453

Hypertension | Chronic Heart Failure

France
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453

Hypertension | Chronic Heart Failure
Bial - Portela C S.A.

Completed

Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients

Parkinson's Disease (PD)
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

Parkinson Disease

United States
Bial - Portela C S.A.

Completed

Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202

Parkinson's Disease

United Kingdom
Bial - Portela C S.A.

Completed

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

Parkinson's Disease (PD)

France
Bial - Portela C S.A.

Completed

Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa

Parkinson Disease

Canada
Bial - Portela C S.A.

Completed

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients. (BIPARKII)

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Effect of Rasagiline on BIA 9-1067 Pharmacokinetics

Parkinson Disease

France
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide

Parkinson's Disease (PD)

Canada
Bial - Portela C S.A.

Completed

Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy Subjects

Epilepsy

France
Bial - Portela C S.A.

Completed

Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate

Epilepsy
Bial - Portela C S.A.

Completed

A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067

Parkinson's Disease

Portugal, Romania, Ukraine
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites

Parkinson Disease

Switzerland
Bial - Portela C S.A.

Completed

Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine

Epilepsy
Bial - Portela C S.A.

Completed

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

Epilepsy

United States
Bial - Portela C S.A.

Completed

Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine

Partial Epilepsy

Belgium
Bial - Portela C S.A.

Completed

Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine

Epilepsy

Germany
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia

Postherpetic Neuralgia
Bial - Portela C S.A.

Terminated

Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain

Painful Diabetic Neuropathy

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy

Partial Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder

Bipolar I Disorder
Bial - Portela C S.A.

Terminated

The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients

Epilepsy

Portugal
Bellos, Nicholaos C., M.D.

Unknown

BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects

HIV Infections

United States
Bial - Portela C S.A.

Active, not recruiting

eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. (ADOPTION)

Parkinson Disease

Spain, Italy, Portugal, Germany, United Kingdom
C. R. Bard
Cromsource

Completed

FLUENCY® PLUS in the Treatment of Peripheral Artery Disease

Vascular Diseases, Peripheral

Germany, Poland
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil

Pulmonary Arterial Hypertension

Germany
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics

Pulmonary Arterial Hypertension

Germany
Bial - Portela C S.A.

Completed

Relative Bioavailability and Bioequivalence of Opicapone

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil

Pulmonary Arterial Hypertension

Germany
Bial - Portela C S.A.

Completed

Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone

Parkinson Disease

Germany
Bial - Portela C S.A.

Completed

Efficacy and Safety of Opicapone in Clinical Practice (OPTIPARK)

Parkinson's Disease With Wearing-off Motor Fluctuations

Germany
Bial - Portela C S.A.

Completed

Pharmacokinetics, Efficacy and Tolerability of BIA 2-093

Epilepsy

Romania
Bial - Portela C S.A.

Completed

Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients

Epilepsy

Spain, Bulgaria, Austria, Croatia, Czechia, France, Germany, Poland, Portugal, Romania
Bial - Portela C S.A.

Completed

The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093

Epilepsy
Bial - Portela C S.A.

Completed

Effect of Food on Opicapone

Parkinson Disease
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453

Hypertension

France
Bial - Portela C S.A.

Completed

Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects

Parkinson Disease

Germany
Bial - Portela C S.A.

Completed

Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 5-453 and Its Metabolites

Hypertension | Chronic Heart Failure

France

3

Subscribe